Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: A systematic review

Journal of the National Cancer Institute

Volumn 104, Issue 17, 2012, Pages 1280-1292

  Dos Santos, Lucas Vieira ^a,b   Souza, Fabiano Hahn ^c   Brunetto, Andre Tesainer ^d,e   Sasse, Andre Deeke ^b   Da Silveira Nogueira Lima, João Paulo ^a,b  

^a BARRETOS CANCER HOSPITAL   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d Health Technology Assessment Institute IATS   (Brazil)

^e HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; APREPITANT; CASOPITANT; DEXAMETHASONE; EZLOPITANT; GRANISETRON; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; SEROTONIN 3 ANTAGONIST;

ANEMIA; ANOREXIA; ASTHENIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; HEADACHE; HICCUP; HUMAN; INFECTION; LEUKOPENIA; META ANALYSIS; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CONFIDENCE INTERVALS; HUMANS; INFECTION; MORPHOLINES; NAUSEA; NEOPLASMS; ODDS RATIO; PIPERAZINES; PIPERIDINES; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, NEUROKININ-1; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; VOMITING;

EID: 84866066733     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs335     Document Type: Review

References (65)

1. Laszlo J, Lucas VS Jr. Emesis as a critical problem in chemotherapy. N Engl J Med. 1981;305(16):948-949. (Pubitemid 11014537)
2. Morran C, Smith DC, Anderson DA, McArdle CS. Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics. Br Med J. 1979;1(6174):1323-1324. (Pubitemid 9172412)
3. Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage. 2007;34(1):94-104. (Pubitemid 46970881)
4. Griffin AM, Butow PN, Coates AS, et al. On the receiving end. V. Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 1996;7(2):189-195. (Pubitemid 26094884)
5. Osoba D, Zee B, Warr D, Kaizer L, Latreille J, Pater J. Quality of life studies in chemotherapy-induced emesis. Oncology. 1996;53(suppl 1):92-95. (Pubitemid 26335156)
6. Wilcox PM, Fetting JH, Nettesheim KM, Abeloff MD. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. Cancer Treat Rep. 1982;66(8):1601-1604. (Pubitemid 12046117)
7. Morrow GR, Lindke J, Black PM. Predicting development of anticipatory nausea in cancer patients: prospective examination of eight clinical characteristics. J Pain Symptom Manage. 1991;6(4):215-223.
8. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15(1):103-109. (Pubitemid 27020563)
9. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1999;17(9):2971-2994. (Pubitemid 29415258)
10. Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Ann Oncol. 1998;9(8):811-819.
11. Kris MG, Hesketh PJ, Somerfield MR, et al.; American Society of Clinical Oncology. American Society of Clinical Oncology guideline for antiemet-ics in oncology: update 2006. J Clin Oncol. 2006;24(18):2932-2947. (Pubitemid 46630595)
12. Roila F, Donati D, Tamberi S, Margutti G. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer. 2002;10(2):88-95. (Pubitemid 36056305)
13. NCCN. NCCN Clinical Practice Guidelines in Oncology: Antiemesis Version 1.2012. Fort Washington, PA: NCCN; 2011.
14. Borison HL, McCarthy LE. Neuropharmacology of chemotherapy-induced emesis. Drugs. 1983;25(suppl 1):8-17. (Pubitemid 13195443)
15. Jantunen IT, Kataja V V, Muhonen TT. An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer. 1997;33(1):66-74. (Pubitemid 27099570)
16. Smith DB, Newlands ES, Rustin GJ, et al. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet. 1991;338(8765):487-490.
17. Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol. 1991;9(4):675-678.
18. Hesketh PJ, Harvey WH, Harker WG, et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol. 1994;12(3):596-600. (Pubitemid 24079904)
19. Hesketh P. Management of cisplatin-induced delayed emesis. Oncology. 1996;53(suppl 1):73-77. (Pubitemid 26335153)
20. Roila F, Bracarda S, Tonato M, et al. Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesis. Clin Oncol (R Coll Radiol). 1990;2(5):268-272.
21. Navari RM, Reinhardt RR, Gralla RJ, et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754, 030 Antiemetic Trials Group. N Engl J Med. 1999;340(3):190-195. (Pubitemid 29063215)
22. Saito R, Takano Y, Kamiya HO. Roles of substance P and NK(1) receptor in the brainstem in the development of emesis. J Pharmacol Sci. 2003;91(2):87-94. (Pubitemid 36575559)
23. Herrstedt J, Roila F. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol. 2008;19(suppl 2):ii110\-ii112.
24. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
25. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ. 1994;309(6964):1286-1291. (Pubitemid 24340510)
26. Verhagen A P, de Vet HC, de Bie RA, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol. 1998;51(12):1235-1241. (Pubitemid 29009523)
27. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12. (Pubitemid 26120810)
28. The Cochrane Collaboration. Review Manager (RevMan). Version 5.0 ed. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2008.
29. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188. (Pubitemid 17189972)
30. Higgins J P, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560. (Pubitemid 37088507)
31. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634. (Pubitemid 27387172)
32. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323(7304):101-105. (Pubitemid 32681979)
33. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-analysis [computer program]. Version 2.2.050. Englewood, NJ: Biostat; 2009.
34. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455-463. (Pubitemid 30422636)
35. Altman DG, Bland JM. Statistics notes. Units of analysis. BMJ. 1997;314(7098):1874.
36. Arpornwirat W, Albert I, Hansen VL, Levin J, Bandekar RR, Grunberg SM. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexametha-sone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy. Cancer. 2009;115(24):5807-5816.
37. Campos D, Pereira JR, Reinhardt RR, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol. 2001;19(6):1759-1767. (Pubitemid 32230878)
38. Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer. 2003;97(9):2290-2300. (Pubitemid 36444075)
39. Cocquyt V, Van Belle S, Reinhardt RR, et al. Comparison of L-758, 298, a prodrug for the selective neurokinin-1 antagonist, L-754, 030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer. 2001;37(7):835-842. (Pubitemid 32323960)
40. de Wit R, Herrstedt J, Rapoport B, et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol. 2003;21(22):4105-4111. (Pubitemid 46606177)
41. Gore L, Chawla S, Petrilli A, et al.; Adolescent Aprepitant in Cancer Study Group. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer. 2009;52(2):242-247.
42. Grunberg SM, Rolski J, Strausz J, et al. Efficacy and safety of caso-pitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(6):549-558.
43. Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexa-methasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer. 2008;112(9):2080-2087. (Pubitemid 351574085)
44. Herrstedt J, Apornwirat W, Shaharyar A, et al. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol. 2009;27(32):5363-5369.
45. Hesketh PJ, Gralla RJ, Webb RT, et al. Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11, 974 in the control of cisplatin-induced emesis. J Clin Oncol. 1999;17(1):338-343. (Pubitemid 29022412)
46. Hesketh PJ, Grunberg SM, Gralla RJ, et al.; Aprepitant Protocol 052 Study Group. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21(22):4112-4119. (Pubitemid 46606178)
47. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al.; Aprepitant Protocol 054 Study Group. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97(12):3090-3098. (Pubitemid 36676265)
48. Rapoport BL, Jordan K, Boice JA, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2010;18(4):423-431.
49. Roila F, Rolski J, Ramlau R, et al. Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. Ann Oncol. 2009;20(11):1867-1873.
50. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexametha-sone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol. 2006;17(6):1000-1006. (Pubitemid 43778994)
51. Van Belle S, Lichinitser MR, Navari RM, et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758, 298 and MK-869. Cancer. 2002;94(11):3032-3041. (Pubitemid 34547705)
52. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepi-tant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23(12):2822-2830. (Pubitemid 46179473)
53. Yeo W, Mo FK, Suen JJ, et al. A randomized study of aprepitant, ondanse-tron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat. 2009;113(3):529-535.
54. Shumway NM, Terrazzino SE, Jones CB, et al. A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy-induced nausea and vomiting. J Clin Oncol. 2009;27(15s):suppl, abstr 9633.
55. Joshi AJ, Singh H, Chawla S. Prevention of chemotherapy induced delayed nausea and vomiting with aprepitant in patients recieving highly emetogenic-five day cisplatin regimens. J Clin Oncol. 2007;25(18s):suppl, abstr 14125.
56. Bubalo JS, Leis JF, Curtin PT, Maziarz RT, Kovascovics TJ, Meyers G, et al. A randomized, double blinded, pilot trial of aprepitant added to standard antiemetics during conditioning therapy for hematopoietic stem cell transplant (HSCT). J Clin Oncol. 2007;25(18s):abstr 9112.
57. Takahashi T, Hoshi E, Takagi M, Katsumata N, Kawahara M, Eguchi K. Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci. 2010;101(11):2455-2461.
58. Coates A, Abraham S, Kaye SB, et al. On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983;19(2):203-208. (Pubitemid 13155858)
59. Kris MG. Why do we need another antiemetic? Just ask. J Clin Oncol. 2003;21(22):4077-4080. (Pubitemid 46606172)
60. Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005;23(6):1289-1294. (Pubitemid 46202287)
61. McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther. 2003;74(1):17-24. (Pubitemid 36776172)
62. Beer S, Weighardt H, Emmanuilidis K, et al. Systemic neuropeptide levels as predictive indicators for lethal outcome in patients with postoperative sepsis. Crit Care Med. 2002;30(8):1794-1798. (Pubitemid 34879593)
63. Chavolla-Calderón M, Bayer MK, Fontán JJ. Bone marrow transplantation reveals an essential synergy between neuronal and hemopoietic cell neurokinin production in pulmonary inflammation. J Clin Invest. 2003;111(7):973-980. (Pubitemid 36397473)
64. Verdrengh M, Tarkowski A. The impact of substance P signalling on the development of experimental staphylococcal sepsis and arthritis. Scand J Immunol. 2008;67(3):253-259. (Pubitemid 351197166)
65. Cai T, Parast L, Ryan L. Meta-analysis for rare events. Stat Med. 2010;29(20):2078-2089.